Skip to main content
. 2020 Jun 9;10:9330. doi: 10.1038/s41598-020-66458-z

Figure 4.

Figure 4

Saroglitazar treatment ameliorates fatty liver, steatohepatitis and fibrosis. DIAMOND mice were treated with pioglitazone, saroglitazar or vehicle control for 12 weeks along with CDNW or WDSW. Mice were maintained on this diet for 12 weeks prior to the initiation of treatment to develop fatty liver and steatohepatitis. Histology score for (A) steatosis, (B) hepatocyte ballooning, (C) lobular inflammation, (D) NAFLD activity score and (E) fibrosis were quantified. Data are expressed as the mean ± SEM for 6–12 mice per group. ##p < 0.001 compared to CDNW; *p < 0.05, **p < 0.001 compared to WDSW, vehicle control.